FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
pharmaphorum
OCTOBER 19, 2020
The combination therapies had previously been marketed following accelerated approval in November 2018 on the basis of early stage results. The drug’s US label also covers certain patients with chronic lymphocytic leukaemia, including a chemotherapy-free regimen for previously untreated patients. months compared with 4.1
Let's personalize your content